264 related articles for article (PubMed ID: 34244116)
1. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
3. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
6. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
9. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
[TBL] [Abstract][Full Text] [Related]
10. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Plimack ER; Powles T; Stus V; Gafanov R; Nosov D; Waddell T; Alekseev B; Pouliot F; Melichar B; Soulières D; Borchiellini D; McDermott RS; Vynnychenko I; Chang YH; Tamada S; Atkins MB; Li C; Perini R; Molife LR; Bedke J; Rini BI
Eur Urol; 2023 Nov; 84(5):449-454. PubMed ID: 37500340
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
[No Abstract] [Full Text] [Related]
15. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
Rexer H; Bedke J
Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
[No Abstract] [Full Text] [Related]
16. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
17. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
18. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
Capitanio U; Fallara G; Raggi D; Nocera L; Larcher A; Belladelli F; Rowe I; Briganti A; Salonia A; Karakiewicz P; Montorsi F; Martini A; Necchi A
Curr Probl Cancer; 2022 Aug; 46(4):100875. PubMed ID: 35679628
[TBL] [Abstract][Full Text] [Related]
20. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Uemura M; Tomita Y; Miyake H; Hatakeyama S; Kanayama HO; Numakura K; Takagi T; Kato T; Eto M; Obara W; Uemura H; Choueiri TK; Motzer RJ; Fujii Y; Kamei Y; Umeyama Y; di Pietro A; Oya M
Cancer Sci; 2020 Mar; 111(3):907-923. PubMed ID: 31883418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
